Holen Sie sich die Stockscreener-App
5.72
0.00%
0.00
Handel nachbörslich:
5.72
Schlusskurs vom Vortag:
$5.72
Offen:
$5.73
24-Stunden-Volumen:
2.13M
Relative Volume:
2.50
Marktkapitalisierung:
$214.34M
Einnahmen:
$425.17M
Nettoeinkommen (Verlust:
$-92.21M
KGV:
-2.2257
EPS:
-2.57
Netto-Cashflow:
$-67.42M
1W Leistung:
+11.50%
1M Leistung:
+73.86%
6M Leistung:
-4.83%
1J Leistung:
-66.65%
1-Tages-Spanne:
$5.71
$5.74
1-Wochen-Bereich:
$5.00
$5.80
52-Wochen-Spanne:
$3.165
$17.75
Nevro Corp Stock (NVRO) Company Profile
Firmenname
Nevro Corp
Sektor
Branche
Telefon
650-251-0005
Adresse
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Vergleichen Sie NVRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
5.72 | 214.34M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
131.44 | 227.98B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.98 | 156.20B | 16.75B | 1.85B | 1.89B | 1.25 |
|
SYK
Stryker Corp
|
390.48 | 148.86B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.20 | 116.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.82B | 6.60B | 4.16B | 490.10M | 6.93 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-03 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-08-09 | Hochstufung | Citigroup | Sell → Neutral |
| 2024-08-08 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-08-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-05-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-12-21 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-05-31 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2023-01-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-12-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Hold |
| 2022-04-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-11-09 | Herabstufung | Truist | Buy → Hold |
| 2021-08-05 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-05 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-07-09 | Herabstufung | Redburn | Buy → Neutral |
| 2021-07-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-08 | Hochstufung | UBS | Sell → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-11-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-10-22 | Eingeleitet | Oppenheimer | Perform |
| 2019-03-20 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-20 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Sell |
| 2018-11-07 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-07-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-05-08 | Bestätigt | Canaccord Genuity | Buy |
| 2018-05-08 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-08 | Herabstufung | Wells Fargo | Outperform → Market Perform |
Alle ansehen
Nevro Corp Aktie (NVRO) Neueste Nachrichten
Nevro (NYSE:NVRO) Price Target Raised to $5.85 - MarketBeat
Nevro (NYSE:NVRO) Upgraded by Piper Sandler to "Overweight" Rating - MarketBeat
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain? - Yahoo Finance
Globus Medical strengthens SCS market position with $250m Nevro deal - Yahoo Finance
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp.NVRO - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders - Marketscreener.com
Jefferies raises Nevro stock rating, boosts price target to $5.85 - MSN
Stifel maintains GMED buy rating, $92 target amid NVRO buyout - MSN
Jefferies Upgrades Nevro to Hold From Underperform, Adjusts Price Target to $5.85 From $4.50 - Marketscreener.com
Jefferies raises Nevro stock rating, boosts price target to $5.85 By Investing.com - Investing.com Australia
Nevro (NYSE:NVRO) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Needham maintains hold on Globus Medical stock post-acquisition - MSN
Jefferies Upgrades Nevro Corp (NVRO) to Hold - StreetInsider.com
Globus Medical to Acquire Nevro Corp. in Strategic $250 Million Deal - MSN
Jefferies maintains Buy on Globus Medical, target at $105 - MSN
Globus Medical Enters into Merger Agreement with Nevro Corp. - Armenian Reporter
Globus Medical to acquire Nevro for $5.85 per share - MSN
Piper Sandler Upgrades Nevro (NVRO) - Nasdaq
Demystifying Nevro: Insights From 11 Analyst Reviews - Benzinga
Nevro (NVRO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Nevro upgraded to Neutral from Underweight at Piper Sandler - MSN
Piper Sandler Upgrades Nevro to Neutral From Underweight, Adjusts Price Target to $5.85 From $6 - Marketscreener.com
Globus Medical, Inc. entered into a definitive agreement to acquire Nevro Corp. for approximately $250 million. - Marketscreener.com
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Altus Power, Amazon, Nevro - TradingView
Piper Sandler raises Nevro stock to Neutral, cuts target to $5.85 - MSN
Globus Medical to acquire Nevro for $250 million By Investing.com - Investing.com Nigeria
Piper Sandler Upgrades Nevro Corp (NVRO) to Neutral - StreetInsider.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Nevro Corp.NVRO - The Malaysian Reserve
Globus Medical to Acquire Nevro for $250M - MD+DI
Items Tagged with 'joint fusion' - BioWorld Online
Globus Medical buying chronic pain company Nevro for $250M - BioWorld Online
Latham & Watkins Advises Nevro in Acquisition by Globus Medical - Latham & Watkins LLP
BTIG maintains $91 target on Globus Medical stock post-acquisition - MSN
Globus Medical Announces Acquisition of Nevro Corp - TipRanks
Canaccord maintains Buy rating, $101 target on Globus Medical stock - MSN
Nevro Corp Announces Merger Agreement with Globus Medical - TipRanks
Globus Medical Buys Device Maker Nevro In $250M Deal - Law360
Globus Medical to acquire Nevro for $250 million - MSN
Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio - Yahoo Finance
Globus Medical to buy California life sciences firm for $250M - The Business Journals
Globus Medical To Acquire Nevro For $250 Mln - Nasdaq
Nevro Corp (NVRO) PT Raised to $5.85 at Canaccord Genuity - StreetInsider.com
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders - Business Wire
Globus Medical to acquire Nevro for $250M - Mass Device
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Globus Medical to Acquire Nevro -February 06, 2025 at 09:58 am EST - Marketscreener.com
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients - GlobeNewswire
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients - Benzinga
Major Medical Device Acquisition: Globus Medical Takes Over Nevro in Strategic $250M Pain Tech Deal - StockTitan
Nevro (NVRO) Cash-to-Debt : 1.12 (As of Sep. 2024) - GuruFocus.com
Finanzdaten der Nevro Corp-Aktie (NVRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):